

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees Mr P Gwilliam (Chairman)
Mr D Jones
Mrs M Phillips
Mrs R Littlejohn
Dr R Srirajaskanthan
Mrs I Wotherspoon

Charity number 1092386

Principal address Second Floor
Holly House
74 Upper Holly Walk
Leamington Spa
Warwickshire
CV32 4JL

Independent examiner Chapman Worth Limited
6 Newbury Street
Wantage
Oxfordshire
OX12 8BS

Bankers Lloyds Bank
Butler Place Branch
PO Box 100
BX1 1LT

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION CONTENTS

	Page
Trustees' report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Statement of financial position	7
Notes to the financial statements	8 - 16

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2019

The Trustees have pleasure in presenting the Trustees' Report and Accounts of the NET Patient Foundation for the year ended 30 September 2019. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016)

Objectives and activities

The constitutional Objects of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognize, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness and influencing improvements in outcomes.

The Values we believe in are (i) equality of care for all NET patients in the UK (ii) excellence in support, care, treatment and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency and integrity to promote confidence and trust in the charity.

Terminology, purpose and need

The umbrella name for neuroendocrine cancers was changed by the World Health Organisation in 2017 to neuroendocrine neoplasms (NENs), incorporating neuroendocrine tumours and neuroendocrine carcinomas. NENs are a group of unusual and unpredictable tumours which develop from cells in the diffuse endocrine system. NENs can affect people of any age and can be benign (non-cancerous) or malignant (cancerous). The NET Patient Foundation supports patients with malignant NENs (neuroendocrine cancer) which are found most commonly in the lung or gastrointestinal system. Every year about 5,000 people are diagnosed with NENs in the UK with around 40,000 living with the disease. Incidence has increased from 4.6 per 100,000 to 8.7 per 100,000 recorded in 2016.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, sadness and anxiety. For NEN patients specifically the prospect of a cure is often nil and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis they can often be treated for the wrong disease meaning their cancer pathway begins with feelings of extreme frustration. At all stages of their treatment NEN patients are also less likely to receive written information about their cancer and its side effects. This is highlighted by the 2014 National Cancer Patient Survey which found that only half of neuroendocrine cancer patients were given written information about all of their tests compared with 91% of cancer patients in general.

After treatment patients have to address the gravity of their diagnosis at home and often without regular access to the support of doctors and nurses. Therefore patients frequently suffer from feelings of abandonment and struggle to know in whom to confide. Indeed, if their cancer is particularly advanced, they face the possibility of dying. From our experience the complexity of NENs means that patients friends and family often struggle to comprehend their suffering.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2019

People with a less common cancer like NENs are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experience and to take positive and meaningful steps to address them.

Achievements and performance

NPF services provided during the year were unchanged but it is worth noting the increase in engagement in the community from 4,000 to now over 6,000 people affected by neuroendocrine cancer on our database.

The CEO is supported by a full-time specialist nurse and a team of administrative and communications staff. An additional full-time specialist nurse is to be recruited in 2020.

A dedicated group of patient ambassadors also support the work of the organization. This group was put together in 2019 and has achieved much in its inaugural year including the first patient led presentation at the national medical conference run by UKINETs with hugely positive feedback.

- A new and updated patient handbook was produced.
- Four patient education events were held in line with current strategy with a new strategy formulated to ensure that events are run based on patient need.
- The use of our psychotherapy service doubled in the year and we have been working with the team to find other ways to support psychological need. A living well course is being planned as is an online mindfulness course adapted for the neuroendocrine cancer community.
- Our patient support groups continue with one new venue in London established.
- Development of a patient self-management tool in the form of an App in collaboration with UKINETs and Ampersand Health is near completion.
- Publication of the first age adjusted incidence and prevalence data on neuroendocrine cancers.
- Development of the MIND the Gap Campaign focusing heavily on the psychological issues that patients and their loved one's face. Poster presented at ESMO.
- Establishment of our NPF Ambassadors group.
- Formulation of a specialist lung patient group and the development of a new lung booklet.
- Development of a media plan to improve the way in which we communicate with our community including the use of podcasts and animations.
- Presentations at national and international meetings and teaching sessions for junior doctors, trainee GP's and the nursing community.
- Our CEO elected as the next President of the International Neuroendocrine Cancer Alliance.

Note from the CEO Cathy Bouvier

There are multiple components to running a patient organization. We are a 'small but vital charity' doing a wide range of activities, ensuring that the message we are shouting gets heard across many platforms, with the ultimate goal of working in a truly collaborative way, with compassion, and providing the best care for all affected by neuroendocrine cancer (NC).

One of our key outcomes is to ensure that all the cogs in the NC pathway are listening to the patient's perspective and focusing conversations on Quality of Life: how we can all best help patients manage and live with their illness. We have undertaken work this year looking at the overriding emotions of an NC diagnosis and have seen clearly that Quality of Life is a personal perception that differs between people even with the same clinical condition. We need to feed this work time and time again into the inboxes of those treating NC patients. Advocacy organisations have an essential role to play, working in partnership with the medical community to identify issues and improve diagnosis, care and research. The quality of communication between the patient and the medical team has an enormous impact on the quality of care. Understanding each other's perspective is the key.

We couldn't progress our work without the support of our volunteers, our dedicated trustees, our Patron Professor Martyn Caplin, our Advisory Board, our fundraisers and sponsors. A heartfelt thanks to all of them and we hope to keep developing strong relationships with the key stakeholders in NCs, keep pushing an agenda for change and improving our organization to meet the needs of our community.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2019

Note from the Chair Peter Gwilliam

On behalf of the trustees I confirm our delight in the growth of the NPF and the strengths of our team and all they are achieving. This is all under the direction of the co-founder and Chief Executive Cathy Bouvier who gives so much in her role across the 5 pillars of NPF activity. Our thanks to you all and to the specialists, consultants and other helpers who give their time. We are of course totally dependent on grants and charitable donations and are so grateful to all our supporters.

This is also an opportunity to thank my fellow trustees for all their hard work in focusing on our vision, mission and values. The positive feedback received confirms that the NPF is making a big difference to so many lives. This report informs that we are certainly 'punching above our weight' and we will all continue to strive to achieve so much more.

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £6,455 for the year (2018 £12,740 deficit) which will be utilised during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the trustees.

At the reporting date the charity held funds of £465,411 (2018 £458,956) and the trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. This level of reserves is in line with the reserves policy of the charity and ensures that it can prepare these accounts on a going concern basis with sufficient contingency if the level of grants and donations should fall during a period of increased economic uncertainty.

Structure, governance and management

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objects of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2019

The trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NPF projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

In addition the NPF is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the Foundation team cannot resolve.

The trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr P Gwilliam (Chairman)

Mr D Jones

Mrs M Phillips

Mrs R Littlejohn

Dr R Srirajaskanthan

Mrs I Wotherspoon

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The trustees' report was approved by the Board of Trustees.

.....
Mr P Gwilliam (Chairman)

Trustee

Dated:

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2019.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act;
or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Anna Chapman FCA
Chapman Worth Limited
6 Newbury Street
Wantage
Oxfordshire
OX12 8BS

Dated:

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2019**

	Notes	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £	Total 2018 £
<u>Income from:</u>					
Donations and legacies	3	317,763	-	317,763	243,794
Grants	4	17,310	49,536	66,846	121,383
Investments	5	150	-	150	46
Total income		<u>335,223</u>	<u>49,536</u>	<u>384,759</u>	<u>365,223</u>
<u>Expenditure on:</u>					
Raising funds	6	8,336	-	8,336	6,218
Charitable activities	7	288,570	81,398	369,968	371,745
Total resources expended		<u>296,906</u>	<u>81,398</u>	<u>378,304</u>	<u>377,963</u>
Net income/(expenditure) for the year/ Net movement in funds		38,317	(31,862)	6,455	(12,740)
Fund balances at 1 October 2018		<u>386,113</u>	<u>72,843</u>	<u>458,956</u>	<u>471,696</u>
Fund balances at 30 September 2019		<u><u>424,430</u></u>	<u><u>40,981</u></u>	<u><u>465,411</u></u>	<u><u>458,956</u></u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL POSITION**

AS AT 30 SEPTEMBER 2019

	Notes	2019 £	£	2018 £	£
Current assets					
Debtors	14	2,051		-	
Cash at bank and in hand		465,807		461,817	
		<u>467,858</u>		<u>461,817</u>	
Creditors: amounts falling due within one year	15	<u>(2,447)</u>		<u>(2,861)</u>	
Net current assets			<u>465,411</u>		<u>458,956</u>
Income funds					
Restricted funds	17		40,981		72,843
Unrestricted funds - general			424,430		386,113
			<u>465,411</u>		<u>458,956</u>

The financial statements were approved by the Trustees on

.....
Mr P Gwilliam (Chairman)
Trustee

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2019

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019

1 Accounting policies

(Continued)

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

1.5 Resources expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Costs of raising funds

The costs of generating funds consist of investment management costs and certain legal fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019**

1 Accounting policies

(Continued)

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019**

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

3 Donations and legacies

	Unrestricted funds general 2019 £	Total 2018 £
Donations and gifts	317,763	243,794
	<u> </u>	<u> </u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019**

4 Grants

	Ipsen	Novartis	Imaging Equipment	Victory Net	Total 2019	Total 2018
	2019	2019	2019	2019		
	£	£	£	£	£	£
Performance related grants	30,000	12,000	9,846	15,000	66,846	121,383
Analysis by fund						
Unrestricted funds - general	-	-	2,310	15,000	17,310	71,383
Restricted funds	30,000	12,000	7,536	-	49,536	50,000
	30,000	12,000	9,846	15,000	66,846	121,383
For the year ended 30 September 2018						
Unrestricted funds - general	-	-	-	71,383		71,383
Restricted funds	-	-	50,000	-		50,000
	-	-	50,000	71,383		121,383

5 Investments

	Unrestricted funds general 2019 £	Total 2018 £
Interest receivable	150	46

6 Raising funds

	Unrestricted funds general 2019 £	Total 2018 £
<u>Fundraising and publicity</u>		
Other fundraising costs	8,336	6,218
	8,336	6,218

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019

6 Raising funds **(Continued)**

7 Charitable activities

	2019	2018
	£	£
Staff costs	118,030	133,923
Charitable activities	67,494	68,051
Computer costs	1,818	1,097
Advertising and marketing	4,469	9,392
Travel and subsistence	9,308	7,849
Rent	10,413	8,564
Telephone	3,216	3,713
	214,748	232,589
Grant funding of activities (see note 9)	25,000	-
Share of support costs (see note 10)	123,592	134,757
Share of governance costs (see note 10)	6,628	4,399
	369,968	371,745
Analysis by fund		
Unrestricted funds - general	288,570	313,588
Restricted funds	81,398	58,157
	369,968	371,745
For the year ended 30 September 2018		
Unrestricted funds - general	313,588	
Restricted funds	58,157	
	371,745	

8 Description of charitable activities

Expenditure to support the primary activity

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

9 Grants payable

	2019	2018
	£	£
Oxford University vis UKINETS	25,000	-
	25,000	-

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019

9 Grants payable

(Continued)

10 Support costs

	Support costs	Governance costs	2019	2018	Basis of allocation
	£	£	£	£	
Staff costs	77,143	-	77,143	79,496	Administrative staff
Office expenses	27,141	-	27,141	20,842	100% of the cost
Legal and professional	4,831	-	4,831	18,589	100% of the cost
Computer costs	5,174	-	5,174	3,123	74% of the cost
Rent and rates	2,603	-	2,603	2,141	20% of the cost
Telecommunications	2,144	-	2,144	2,475	40% of the cost
Other costs	4,556	-	4,556	8,091	100% of the cost
Audit fees	-	5,394	5,394	3,842	Governance
Trustees expenses	-	1,234	1,234	557	Governance
	<u>123,592</u>	<u>6,628</u>	<u>130,220</u>	<u>139,156</u>	
Analysed between					
Charitable activities	<u>123,592</u>	<u>6,628</u>	<u>130,220</u>	<u>139,156</u>	

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the Independent Examiner of £1,510 (2018- £1,500) for the Independent Examination.

11 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year, but travelling expenses of £208 and meeting expenses of £881 were reimbursed (2018- £470).

During the year Trustees donated a total of £240 (2018 - £240) to general funds.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019

12 Employees

Number of employees

The average monthly number of employees during the year was:

2019	2018
Number	Number
6	7
<u>6</u>	<u>7</u>

Employment costs

	2019	2018
	£	£
Wages and salaries	177,212	192,043
Social security costs	14,561	16,366
Other pension costs	3,400	5,010
	<u>195,173</u>	<u>213,419</u>

13 Financial instruments

	2019	2018
	£	£
Carrying amount of financial assets		
Debt instruments measured at amortised cost	2,051	-
	<u>2,051</u>	<u>-</u>
Carrying amount of financial liabilities		
Measured at amortised cost	2,447	2,861
	<u>2,447</u>	<u>2,861</u>

14 Debtors

	2019	2018
	£	£
Amounts falling due within one year:		
Other debtors	2,051	-
	<u>2,051</u>	<u>-</u>

15 Creditors: amounts falling due within one year

	2019	2018
	£	£
Other creditors	937	-
Accruals and deferred income	1,510	2,861
	<u>2,447</u>	<u>2,861</u>

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2019

16 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £3,400 (2018:£5,010).

17 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			
	Balance at 1 October 2018	Incoming resources	Resources expended	Balance at 30 September 2019
	£	£	£	£
IEL / Novartis - Data Coding Project	27,000	-	(27,000)	-
IEL - App Project	45,843	15,000	(34,862)	25,981
MCC	-	12,000	(12,000)	-
Office Equipment	-	7,536	(7,536)	-
Ipsen - Publicity/PR	-	15,000	-	15,000
	<u>72,843</u>	<u>49,536</u>	<u>(81,398)</u>	<u>40,981</u>

18 Analysis of net assets between funds

	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £	Total 2018 £
Fund balances at 30 September 2019 are represented by:				
Current assets/(liabilities)	424,430	40,981	465,411	458,956
	<u>424,430</u>	<u>40,981</u>	<u>465,411</u>	<u>458,956</u>

19 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2019 £	2018 £
Aggregate compensation	<u>52,480</u>	<u>49,475</u>